Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock opened at $36.29 on Friday. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $39.15. The firm’s 50-day moving average is $32.90 and its 200 day moving average is $23.68. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -18.05 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). On average, equities analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Tyra Biosciences during the 4th quarter valued at about $51,000. Chung Wu Investment Group LLC purchased a new position in shares of Tyra Biosciences in the fourth quarter worth approximately $53,000. Federated Hermes Inc. grew its position in Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after buying an additional 1,841 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after buying an additional 534 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in Tyra Biosciences during the fourth quarter valued at approximately $220,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on TYRA shares. William Blair initiated coverage on shares of Tyra Biosciences in a report on Tuesday, February 10th. They issued an “outperform” rating for the company. Cantor Fitzgerald started coverage on Tyra Biosciences in a research note on Tuesday, February 24th. They set an “overweight” rating on the stock. HC Wainwright lifted their target price on Tyra Biosciences from $30.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Piper Sandler boosted their price target on Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, March 20th. Finally, Wall Street Zen downgraded Tyra Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tyra Biosciences has an average rating of “Moderate Buy” and an average target price of $44.67.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.